Childhood varicella-zoster virus vaccination in Belgium: Cost-effective only in the long run or without exogenous boosting?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 812-822

  Bilcke, Joke ^a   Van Hoek, Albert Jan ^b   Beutels, Philippe ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Age; Chickenpox; Cost utility; Shingles; Time horizon; Uncertainty; Zostavax

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; ARTICLE; BELGIUM; CHICKENPOX; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HERPES ZOSTER; HUMAN; MORTALITY; QUALITY ADJUSTED LIFE YEAR; SINGLE DRUG DOSE; SOCIAL BEHAVIOR; VACCINATION; VIRUS REACTIVATION;

AGE; CHICKENPOX; COST-UTILITY; SHINGLES; TIME HORIZON; UNCERTAINTY; ZOSTAVAX;

ADOLESCENT; ADULT; AGED; BELGIUM; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HERPES ZOSTER; HUMANS; INFANT; MALE; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 84877105800     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23334     Document Type: Article

References (61)

1. Gershon A, Takahashi M, Seward J. Varicella Vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders 2008:915-58.
2. Hope-Simpson RE. The Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis. Proc R Soc Med 1965; 58:9-20; PMID:14267505.
3. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-90; PMID:4139526; http://dx.doi.org/10.1016/S0140-6736(74)90144-5.
4. VENICE. Varicella and Herpes Zoster surveillance and vaccination recommendations 2010-2011. 2010.
5. Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect 2012; 140:2096-109; PMID:22230041; http://dx.doi.org/10.1017/ S0950268811002640.
6. Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008; 7:753-82; PMID:18665775; http://dx.doi.org/10.1586/14760584.7.6.753.
7. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21:13-38; PMID:12484801; http://dx.doi.org/10.2165/00019053-200321010- 00002.
8. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983; 148:200-5; PMID:6310001; http://dx.doi.org/10.1093/infdis/148.2.200.
9. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20:2500-7; PMID:12057605; http://dx.doi.org/10.1016/S0264- 410X(02)00180-9.
10. Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, et al. Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)? Clin Infect Dis 2011; 53:405-10; PMID:21844022; http://dx.doi.org/10.1093/cid/ cir436.
11. Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect 2011; 139:658-65; PMID:20727248; http://dx.doi.org/10.1017/ S0950268810001949.
12. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52:332-40; PMID:21217180; http://dx.doi.org/10.1093/cid/ciq077.
13. Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, Ieven M, et al. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunol 2011; 24:151-7; PMID:21449725; http://dx.doi.org/10.1089/vim.2010.0031.
14. Ogunjimi B, Van Damme P, Beutels P. Zoster in monasteries: some clarification needed. Clin Infect Dis 2012; 54:305-6, author reply 306-7; PMID:22198994; http://dx.doi.org/10.1093/cid/cir841.
15. Salleras M, Domínguez A, Soldevila N, Prat A, Garrido P, Torner N, et al. Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 2011; 29:7602-5; PMID:21889558; http://dx.doi.org/10. 1016/j.vaccine.2011.08.023.
16. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678-82; PMID:12241874; http://dx.doi.org/10.1016/S0140-6736(02)09837- 9.
17. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5:68; PMID:15960856; http://dx.doi.org/10.1186/1471-2458-5-68.
18. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016.
19. Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts R F, et al. Efficacy, safety, and tolerabil-ity of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8; PMID:22291101; http://dx.doi.org/10.1093/cid/cir970.
20. van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 2012; 30:1225-34; PMID:22119592; http://dx.doi.org/10.1016/j.vac-cine.2011.11.026.
21. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine 2012; 30:2795-800; PMID:21964056; http://dx.doi.org/10.1016/j.vaccine.2011.09.079.
22. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward J F. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7; PMID:15897984; http://dx.doi.org/10.1086/430325.
23. Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, et al.; Viral Hepatitis Prevention Board. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20:1-7; PMID:11817988; http://dx.doi.org/10.2165/00019053-200220010- 00001.
24. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumo-coccal conjugate vaccination-a review (2002-2006). Vaccine 2007; 25:1355-67; PMID:17208339; http://dx.doi.org/10.1016/ j.vaccine.2006.10.034.
25. Bilcke J, Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009; 27:281-97; PMID:19485425; http://dx.doi.org/10.2165/ 00019053-200927040-00002.
26. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10:751-74; PMID:11747055; http://dx.doi.org/10.1002/hec.625.
27. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16:1-31; PMID:10167341; http://dx.doi.org/10.1016/ S0167-6296(96)00506-1.
28. Luyten J, Vandevelde A, Van Damme P, Beutels P. Vaccination Policy and Ethical Challenges Posed by Herd Immunity, Suboptimal Uptake and Subgroup Targeting. Public Health Eth-Uk 2011; 4:280-91; http://dx.doi.org/10.1093/phe/ phr032.
29. Chaves SS, Zhang J, Civen R, Watson BM, Carbajal T, Perella D, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis 2008; 197(Suppl 2):S127-31; PMID:18419385; http://dx.doi.org/10.1086/522150.
30. Salvadori M. Preventing varicella: Recommendations for routine two-dose varicella immunization in children. Paediatr Child Health 2011; 16:415-6; PMID:22851897.
31. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al.; Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320-8; PMID:22828595; http://dx.doi.org/10.1093/cid/cis638.
32. Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007; 35:326-33; PMID:17710370; http://dx.doi.org/10.1007/s15010-007-6337-z.
33. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella- varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25:12-8; PMID:16395096; http://dx.doi.org/10.1097/01.inf.0000195626.35239.58.
34. Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, et al.; Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin 2006; 2:205-14; PMID:17035730; http://dx.doi.org/10.4161/hv.2.5.3246.
35. Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005; 24:665-9; PMID:16094217; http://dx.doi.org/10.1097/01.inf.0000172902.25009.a1.
36. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174(Suppl 3):S335-41; PMID:8896542; http://dx.doi.org/10.1093/infdis/174. Supplement-3.S335.
37. Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21:1256-67; PMID:12559807; http://dx.doi.org/10.1016/S0264- 410X(02)00431-0.
38. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113-25; PMID:11803072; http://dx.doi.org/10.1016/ S0264-410X(01)00437-6.
39. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88:862-9; PMID:14500303; http://dx.doi.org/10.1136/adc.88.10.862.
40. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 1999; 18:407-15; PMID:10519929; http://dx.doi.org/10.1016/S0264-410X(99)00261-3.
41. Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22:3546-62; PMID:15315834; http://dx.doi.org/10.1016/j.vaccine. 2004.03.043.
42. Beutels P. Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. Antwerp: University of Antwerp (ISBN 90-9015528-7), 2002:523.
43. Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV, et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 2002; 161:588-93; PMID:12424583; http://dx.doi.org/10. 1007/s00431-002-1053-2.
44. Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, et al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. KCE reports 151 2011; (https://kce.fgov.be/nl/ publication/report/kosteneffectiviteit-van-vaccinatie-tegen-windpokken-bij- kinderen-en-tegen-zona-bi).
45. Lamont R F, Sobel JD, Carrington D, Mazaki-Tovi S, Kusanovic J P, Vaisbuch E, et al. Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG 2011; 118:1155-62; PMID:21585641; http://dx.doi.org/10.1111/j.1471-0528. 2011.02983.x.
46. van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 2011; 29:2411-20; PMID:21277405; http://dx.doi.org/10.1016/j.vaccine.2011.01.037.
47. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125:651-69; PMID:11218215; http://dx.doi.org/10.1017/S0950268800004714.
48. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140:81-104; PMID:8023813.
49. Goeyvaerts N, Hens N, Aerts M, Beutels P. Model structure analysis to estimate basic immunologi-cal processes and maternal risk for parvovirus B19. Biostatistics 2011; 12:283-302; PMID:20841333; http://dx.doi.org/10.1093/ biostatistics/kxq059.
50. Goeyvaerts N, Hens N, Ogunjimi B, Aerts M, Shkedy Z, Van Damme P, et al. Estimating infectious disease parameters from data on social contacts and serological status. J R Stat Soc 2010; 59:255-77; http://dx.doi.org/10.1111/j. 1467-9876.2009.00693.x.
51. Ogunjimi B, Hens N, Goeyvaerts N, Aerts M, Van Damme P, Beutels P. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci 2009; 218:80-7; PMID:19174173; http://dx.doi.org/10.1016/j.mbs.2008.12.009.
52. Hens N, Aerts M, Shkedy Z, Theeten H, Van Damme P, Beutels P. Modelling multisera data: the estimation of new joint and conditional epidemiological parameters. Stat Med 2008; 27:2651-64; PMID:17972342; http://dx.doi.org/10.1002/ sim.3089.
53. Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012; 30:675-84; PMID:22120193; http://dx.doi.org/10. 1016/j.vaccine.2011.10.036.
54. Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010; 29:73-5; PMID:19907361; http://dx.doi.org/10.1097/INF.0b013e3181b41506.
55. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006; 24:1308-14; PMID:16352376; http://dx.doi.org/10.1016/j.vaccine.2005.09.026.
56. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010; 26:656-66; PMID:20842005.
57. Hoppenbrouwers K, Vandermeulen C, Roelants M, Boonen M, Depoorter A, Van Damme P, et al. Studie van de vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2008. KULeuven, in opdracht van Ministerie Welzijn en Gezin van de Vlaamse Gemeenschap 2008; http://www.zorg-en-gezondheid.be/uploadedFiles/ NLsite/Preventie/Infectieziekten-en-vaccinaties/Vaccinaties/professionelen/ vaccinatiegraad/VCOV-fulltekst-2009-02-06-text.pdf.
58. Swennen B, Robert E. Enquête de couverture vaccinale en Communauté française, Bruxelles excepté. Provac 2009.
59. Swennen B. Enquête de couverture vaccinale en Communauté française, Bruxelles excepté. Provac 2006.
60. Cleemput I, Neyt M, Van De Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. KCE reports 183C 2011; (https://kce.fgov.be/publication/report/belgian-guidelines-for- economic-evaluations-and-budget-im-pact-analyses-second-edi).
61. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. New York: Oxford University Press, 2006.